NCT00628212View on ClinicalTrials.gov

Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

324

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

January 31, 2009

Conditions
Type 2 Diabetes
Interventions
DRUG

Teneligliptin 10mg

DRUG

Teneligliptin 20 mg

DRUG

Teneligliptin 40 mg

DRUG

Placebo

Trial Locations (1)

Unknown

Takikawa-shi

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY